Search results for "Angiotensin"

showing 10 items of 396 documents

Effects of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised controlled study versus hydrochlorothiazide.

1995

In this study the efficacy and safety of short-term cilazapril administration on renal haemodynamics were evaluated in mild to moderate hypertensive subjects. Our final goal was to evaluate whether the reduction in blood pressure achieved by treatment was associated with maintained renal function. After a run-in period with placebo, 40 hypertensive subjects without renal or cardiac diseases were randomly allocated to a double-blind 4 week controlled trial with cilazapril 5 mg once a day (20 patients) or hydrochlorothiazide 25 mg once a day (20 patients). Renal haemodynamics measurements included effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) by radionuclide study us…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaUrologyRenal functionAngiotensin-Converting Enzyme InhibitorsCilazaprilEssential hypertensionRenal CirculationHydrochlorothiazideDouble-Blind MethodInternal medicineInternal MedicinemedicineAngiotensin-Converting Enzyme InhibitorsAntihypertensive Agents Hydrochlorothiazide CilazaprilHumansAntihypertensive AgentsAgedRenal circulationbusiness.industryHemodynamicsGeneral MedicineEffective renal plasma flowCilazaprilMiddle Agedmedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareFiltration fractionmedicine.anatomical_structureEndocrinologyHydrochlorothiazideTreatment OutcomeRenal blood flowHypertensionSettore BIO/14 - FarmacologiaFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugGlomerular Filtration RateBlood pressure
researchProduct

Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects

2003

Fifty-six young central obese patients were investigated to evaluate relationships between soluble E-selectin (sE-S), angiotensin-converting enzyme (ACE) gene polymorphism, left ventricular function and structure, and carotid morphology by determination of sE-S and ACE genotypes. Our results indicated that central obese subjects with concomitant higher levels of sE-S and ACE DD genotype may be characterized by early cardiovascular alterations and then considered a particular subset of subjects at higher risk of cardiovascular disease.

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internaangiotensin-converting-enzyme cardiovascular damageGenotypeArteriosclerosisEndocrinology Diabetes and MetabolismBlood PressureDiseasecentral obese subjectsPeptidyl-Dipeptidase ABody Mass Indexcirculating E-selectin genotype; angiotensin-converting-enzyme cardiovascular damage; central obese subjectsEndocrinologyRisk FactorsInternal medicineGenotypeE-selectinmedicineHumansInsulinObesityAllelesbiologyVentricular functionHemodynamicsHeartAngiotensin-converting enzymeGlucose Tolerance TestSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheIsoenzymesCarotid ArteriesEndocrinologyCardiovascular DiseasesEchocardiographyConcomitantbiology.proteinRegression AnalysisFemaleObese subjectsGene polymorphismE-Selectincirculating E-selectin genotypeMetabolism
researchProduct

Body weight changes and the A-6G polymorphism of the angiotensinogen gene

2002

BACKGROUND: The objective of the study was to analyze the relationship of polymorphisms of the angiotensinogen gene with changes in body weight during 3 y of antihypertensive treatment, in a group of young adults with essential hypertension. METHODS: Essential hypertensives, less than 50 y old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only non-pharmacological measures (n=29), β-blockers (n=40) or angiotensin-converting enzyme inhibitors (n=66). Resting blood pressure, biochemical profile and body weight at the beginning and yearly were measured. The polymorphism A-6G …

AdultMalemedicine.medical_specialtyTime FactorsGenotypeEndocrinology Diabetes and MetabolismAdrenergic beta-AntagonistsAngiotensinogenMedicine (miscellaneous)Angiotensin-Converting Enzyme InhibitorsEssential hypertensionBody Mass IndexGene FrequencyPolymorphism (computer science)Diabetes mellitusInternal medicineGenotypeHumansMedicineAllele frequencyAntihypertensive AgentsAnalysis of VariancePolymorphism GeneticNutrition and Dieteticsbusiness.industryBody WeightMiddle Agedmedicine.diseaseBlood pressureEndocrinologyHypertensionFemalemedicine.symptombusinessBody mass indexWeight gainFollow-Up StudiesInternational Journal of Obesity
researchProduct

One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.

2009

BACKGROUND AND OBJECTIVES: Hypertension is a significant cause of chronic renal injury and its effective treatment is capable of reducing the rate of renal failure. beta-Adrenoceptor antagonists (beta-blockers) have been reported to induce a deterioration in renal function, while several data have indicated a renoprotective effect of treatment with the angiotensin II type 1 receptor antagonist losartan. Previous studies of the interaction between the selective beta(1)-blocker bisoprolol and kidney function were performed only for short- and medium-term periods. The aim of this study was to compare the antihypertensive efficacy and renal and cardiac haemodynamic effects of bisoprolol with th…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classRenal functionHemodynamicsEssential hypertensionKidneyKidney Function TestsLosartanlaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineBisoprololHumansPharmacology (medical)Antihypertensive Agentshypertension losartanbisiprololbusiness.industryHeartGeneral MedicineMiddle AgedReceptor antagonistmedicine.diseaseAngiotensin IILosartanBisoprololHeart Function TestsHypertensionCardiologyFemalebusinessmedicine.drug
researchProduct

PSYCHIATRIC DISTURBANCE LEADING TO POTASSIUM DEPLETION, SODIUM DEPLETION, RAISED PLASMA-RENIN CONCENTRATION, AND SECONDARY HYPERALDOSTERONISM

1968

Abstract Nine psychiatrically disturbed women were studied, variously suffering from the effects of anorexia nervosa, vomiting, and abuse of diuretics and purgatives. Each had more than one source of electrolyte depletion, and each deliberately concealed at least one of these. All were potassium-depleted, and in all but one sodium depletion was also evident. During exacerbations plasma-renin concentration was raised, secretion-rate and plasma concentration of aldosterone were increased, and the metabolic clearance of aldosterone was diminished. It is suggested that in combined sodium and potassium deficiency, conservation of sodium may be relatively more effective than that of potassium, an…

Adultmedicine.medical_specialtyAnorexia NervosaSubstance-Related DisordersVomitingSodiumPotassiumchemistry.chemical_elementPlasma renin activitychemistry.chemical_compoundInternal medicineHyperaldosteronismReninRenin–angiotensin systemmedicineHumansPotassium DeficiencySecondary hyperaldosteronismAldosteroneChemistryMental DisordersGeneral Medicinemedicine.diseaseHyperaldosteronismEndocrinologyFemalePotassium deficiencyHyponatremiaThe Lancet
researchProduct

Studies on the mechanism of mineralocorticoid-induced blood pressure increase in man.

1979

1. To gain insight into the mechanism of mineralocorticoid-induced blood pressure rise in man we performed haemodynamic studies in six normotensive volunteer subjects before and during administration of the synthetic steroid 9α-fluorocortisol (0·8 mg daily) for a period of 6 weeks. In a further study, performed in seven subjects, plasma noradrenaline concentration and reactivity to exogenous noradrenaline were determined before and during administration of the mineralocorticoid. 2. Within the first week of steroid administration an increase in mean arterial blood pressure could be demonstrated, which was due to an increase in cardiac output. After the sixth week the elevated blood pressure …

Adultmedicine.medical_specialtyCardiac outputSympathetic Nervous SystemEpinephrinemedicine.drug_classmedicine.medical_treatmentHemodynamicsBlood PressureSteroidNorepinephrineHeart RateInternal medicineReninmedicineHumansCardiac OutputVolunteerChemistryAngiotensin IIGeneral MedicineEndocrinologyBlood pressurePressor responseMineralocorticoidFludrocortisoneBlood pressure increaseClinical science (London, England : 1979)
researchProduct

Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losarta…

2009

Abstract The incidence of cardiovascular diseases in premenopausal women is lower than in men or postmenopausal women. This study reports the discovery of a low grade of systemic inflammation, including monocyte adhesion to arterial endothelium, elicited by menopause or estrogen depletion. Chronic treatment with low dose of 17-β-estradiol or inhibition of the renin-angiotensin system reduced this inflammation. Using an in vitro flow chamber system with human arterial and venous endothelial cells, we found that leukocytes from healthy postmenopausal women were more adhesive to the arterial endothelium than those from premenopausal women regardless of the stimulus used on endothelial cells. I…

Adultmedicine.medical_specialtyEndotheliummedicine.drug_classOvariectomyImmunologyInflammationSystemic inflammationLosartanRats Sprague-DawleyInternal medicinemedicineCell AdhesionLeukocytesImmunology and AllergyAnimalsHumansCells CulturedInflammationCell adhesion moleculebusiness.industryEndothelial CellsEstrogensBenzazepinesMiddle Agedmedicine.diseaseRatsMenopausemedicine.anatomical_structureEndocrinologyLosartanEstrogenCase-Control StudiesOvariectomized ratFemaleEndothelium Vascularmedicine.symptomChemokinesMenopausebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion Moleculesmedicine.drugJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Aging modifies receptor expression but not muscular contractile response to angiotensin II in rat jejunum

2022

AbstractThe involvement of renin-angiotensin system in the modulation of gut motility and age-related changes in mRNA expression of angiotensin (Ang II) receptors (ATR) are well accepted. We aimed to characterize, in vitro, the contractile responses induced by Ang II, in jejunum from young (3–6 weeks old) and old rats (≥ 1 year old), to evaluate possible functional differences associated to changes in receptor expression. Mechanical responses to Ang II were examined in vitro as changes in isometric tension. ATR expression was assessed by qRT-PCR. Ang II induced a contractile effect, antagonized by losartan, AT1R antagonist, and increased by PD123319, AT2R antagonist, as well by neural block…

AgingJejunumPhysiologyAngiotensin IIAngiotensin II receptorsIntestinal motilityAnimalsGeneral MedicineReceptor Angiotensin Type 2BiochemistryReceptor Angiotensin Type 1LosartanRats
researchProduct

The rxr agonist bexarotene in combination with rosuvastatin inhibits angiotensin-ii induced abdominal aortic aneurysm formation in apoliprotein -e-kn…

2014

AgonistBexarotenemedicine.medical_specialtybusiness.industrymedicine.drug_classPharmacologyRetinoid X receptormedicine.diseaseAngiotensin IIAbdominal aortic aneurysmEndocrinologyInternal medicineKnockout mouseMedicineRosuvastatinCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

Progesterone increases basal 3',5'-cyclic adenosine monophosphate formation and down-regulates the agonist-induced inositol phosphates generation in …

1992

Whether the placenta is a target tissue for estrogens and progesterone, and their putative mechanism of action, is still a controversial question in the literature. The effect of progesterone and estradiol on 3′,5′-cyclic adenosine monophosphate (cAMP) and inositol phosphates generation in human term placenta was investigated. Placental explants were incubated in vitro for up to 48 h in the absence and in the presence of estradiol, progesterone or both steroids (0.1 μmol/l final concentration in all cases), and were stimulated with terbutaline, a β-adrenergic agonist, (0.1 mmol/l) or angiotensin II(1 μmol/l), The cAMP content was measured by a competitive protein binding assay, and the gene…

Agonistmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismInositol PhosphatesPlacentaDown-RegulationBiologychemistry.chemical_compoundEndocrinologyPregnancyInternal medicinePlacentamedicineCyclic AMPTerbutalineHumansCyclic adenosine monophosphateInositolInositol phosphateProgesteronechemistry.chemical_classificationLabor ObstetricEstradiolAngiotensin IIGeneral MedicineTrypan BlueChromatography Ion ExchangeAngiotensin IIEndocrinologymedicine.anatomical_structurechemistryEstrogenSecond messenger systemLactatesFemaleActa endocrinologica
researchProduct